Ellipticine cytotoxicity to cancer cell lines-a comparative study

Interdisciplinary Toxicology

Volumn 4, Issue 2, 2011, Pages 98-105

  Stiborová, Marie ^a   Poljaková, Jitka ^a   Martínková, Eva ^a   Bořek Dohalská, Lucie ^a   Eckschlager, Tomáš ^b   Kizek, Rene ^c   Frei, Eva ^d  

^a CHARLES UNIVERSITY   (Czech Republic)

^b UNIVERSITY HOSPITAL MOTOL   (Czech Republic)

^c MENDEL UNIVERSITY IN BRNO   (Czech Republic)

^d GERMAN CANCER RESEARCH CENTER DKFZ   (Germany)

Author keywords

cancer cell lines; DNA adducts; Ellipticine; mechanims of acticancer effects of ellipticine

Indexed keywords

12 HYDROXYELLIPTICINE; 13 HYDROXYELLIPTICINE; CELL DNA; CYTOCHROME P450; CYTOTOXIC AGENT; ELLIPTICINE; PEROXIDASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CELL STRAIN HL 60; CELL STRAIN MCF 7; CONCENTRATION RESPONSE; CONTROLLED STUDY; COVALENT BOND; DNA ADDUCT; DRUG CYTOTOXICITY; DRUG DNA BINDING; DRUG EFFECT; DRUG EFFICACY; DRUG SENSITIVITY; DRUG STRUCTURE; GLIOMA CELL; HUMAN; HUMAN CELL; NEUROBLASTOMA CELL;

EID: 79959467727     PISSN: 13376853     EISSN: 13379569     Source Type: Journal    
DOI: 10.2478/v10102-011-0017-7     Document Type: Article

References (33)

1. Aimová D, Svobodová L, Kotrbová V, Mrázová B, Hodek P, Hudecek J, Vá-clavíková R., Frei E. (2007). The anticancer drug ellipticine is a potent in-ducer of rat cytochromes P450 1A1 and 1A2, thereby modulating its own metabolism. Drug Metab Dispos 35: 1926-1934. (Pubitemid 47481588)
2. Auclair C. (1987). Multimodal action of antitumor agents on DNA: The ellipti-cine series. Arch Biochem Biophys 259: 1-14. (Pubitemid 17164718)
3. Borek-Dohalská L, Frei E and Stiborová M. (2004). DNA adduct formation by the anticancer drug ellipticine and its hydroxy derivatives in human breast adenocarcinoma MCF-7 cells. Collect Czech Chem Commun 69: 603-615. (Pubitemid 38526511)
4. Cinatl J Jr, Cinatl J, Driever PH, Kotchetkov R, Pouckova P, Kornhuber B and Schwabe D. (1997). Sodium valproate inhibits in vivo growth of human neu-roblastoma cells. Anti-Cancer Drugs 8: 958-63. (Pubitemid 28027094)
5. Frei E, Bieler CA, Arlt VM, Wiessler M and Stiborová M. (2002). Covalent binding of the anticancer drug ellipticine to DNA in V79 cells transfected with human cytochrome P450 enzymes. Biochem Pharmacol 64: 289-295. (Pubitemid 34775308)
6. Garbett NC and Graves DE. (2004). Extenting nature's leads: the anticancer agent ellipticine. Curr Med Chem Anti-Cancer Agents 4: 149-72. (Pubitemid 38404690)
7. Huska D, Adam V, Krizkova S, Hrabeta J, Eckschlager T, Stiborova M and Kizek R. (2010a) An electrochemical study of interaction of an anticancer alkaloid ellipticine with DNA. Chim Oggi-Chem Today 28(5) Suppl S: 15-17.
8. Huska D, Adam V, Hubalek J, Trnkova L, Eckschlager T, Stiborova M, Provaznik I and Kizek R. (2010b). Of-line coupling of automated pipetting system with square wave voltammetry as a tool for study of drug-DNA interaction. Chim Oggi-Chem Today 28:(5) Suppl S: 18-20.
9. Fossé P, René B, Charra M, Paoletti C and Saucier JM. (1992). Stimulation of topoisomerase II-mediated DNA cleavage by ellipticine derivatives: structure-activity relationships. Mol Pharmacol 42: 590-595. (Pubitemid 23027620)
10. Froelich-Ammon SJ, Patchan MW, Osherof N and Thompson RB. (1995). Topoisomerase II binds to ellipticine in the absence or presence of DNA. Characterization of enzyme-drug interactions by f uorescence spectros-copy. J Biol Chem 270: 4998-5004.
11. Kuo PL, Hsu YL, Chang CH and Lin CC. (2005a). The mechanism of ellipticine-induced apoptosis and cell cycle arrest in human breast MCF-7 cancer cells. Cancer Lett 223: 293-301.
12. Kuo PL, Hsu YL, Kuo YC, Chang CH and Lin CC. (2005b). The antiprolifera-tive inhibition of ellipticine in human breast mda-mb-231 cancer cells is through cell cycle arrest and apoptosis induction. Anti-Cancer Drugs 16: 789-795.
13. Kuo PL, Kuo YC, Hsu YL, Cho CY and Lin CC. (2006). Ellipticine induced apop-tosis through p53-dependent pathway in human hepatocellular carcinoma HepG2 cells. Life Sci. 78: 2550-2557.
14. Martinkova E, Dontenwill M, Frei E and Stiborova M. (2009). Cytotoxicity of and DNA adduct formation by ellipticine in human U87MG glioblastoma cancer cells. Neuro Endocrinol Lett 30 (Suppl 1): 60-66.
15. Martinkova E, Maglott A, Leger, DY, Bonnet D, Stiborova M, Takeda K, Martin S and Dontenwill M. (2010). α5β1 integrin antagonists reduce chemotherapy-induced premature senescence and facilitate apoptosis in human glio-blastoma cells. Int J Cancer 127: 1240-1248.
16. McCormick DL, Adamowski CB, Fiks A, Moon RC. (1981). Lifetime dose-response relationships for mammary tumor induction by a single administration of N-methyl-N-nitrosourea, Cancer Res 41: 1690-1694. (Pubitemid 11114558)
17. Monnot M, Maufret O, Simon V, Lescot E, Psaume B, Saucier JM, Charra M, Belehradek J Jr and Fermandjian S. (1991). DNA-drug recognition and effects on topoisomerase II-mediated cytotoxicity. A three-mode binding model for ellipticine derivatives. J Biol Chem 25: 1820-1829. (Pubitemid 21908374)
18. Moserová M, Kotrbová V, Rupertová M, Naiman K, Hudecek J, Hodek P, Frei E and Stiborová M. (2008). Isolation and partial characterization of the ad-duct formed by 13-hydroxyellipticine with deoxyguanosine in DNA. Neuro Endocrinol Lett. 29: 728-732.
19. Ohashi M, Sugikawa E and Nakanishi N. (1995). Inhibition of p53 protein phosphorylation by 9-hydroxyellipticine: A possible anticancer mechanism. Jpn J Cancer Res 86: 819-829.
20. Poljaková J, Dracínský M, Frei E., Hudecek J and Stiborová M. (2006). The effect of pH on peroxidase-mediated oxidation of and DNA-adduct formation by ellipticine. Collect Czech Chem Commu. 71: 1169-1185. (Pubitemid 44432311)
21. Poljaková J, Frei E, Gomez JE, Aimová D, Eckschlager T, Hrabeta J and Stiborová M. (2007). DNA adduct formation by the anticancer drug ellipticine in human leukemia HL-60 and CCRF-CEM cells. Cancer Lett 252: 270-279. (Pubitemid 46809792)
22. Poljaková J, Eckschlager T, Hrabeta J, Hrebacková J, Smutný S, Frei E, Mar-tínek V, Kizek R and Stiborová M. (2009). The mechanism of cytotoxicity and DNA adduct formation by the anticancer drug ellipticine in human neuroblastoma cells. Biochem Pharmacol 77: 1466-1479.
23. Singh M P, Hill GC, Peoch D, Rayner, B, Inabach, JL and Lown JW. (1994). High-f eld NMR and restrained molecular modeling studies on a DNA heterodu-plex containing a modif ed apurinic abasic site in the form of covalently linked 9-aminoellipticine. Biochemistry 33: 10271-10285. (Pubitemid 24281792)
24. Stiborová M, Bieler CA, Wiessler M and Frei E. (2001). The anticancer agent el-lipticine on activation by cytochrome P450 forms covalent DNA adducts. Biochem Pharmacol 62: 675-684.
25. 32P-postlabeling. Int J Cancer 107: 885-890. (Pubitemid 37429828)
26. Stiborová M, Stiborová-Rupertová M, Borek-Dohalská L, Wiessler M, Frei E. (2003b). Rat microsomes activating the anticancer drug ellipticine to species covalently binding to deoxyguanosine in DNA are a suitable model mimicking ellipticine bioactivation in humans. Chem Res Toxicol 16: 38-47. (Pubitemid 36139409)
27. 2-oxide. Cancer Res 64: 8374-8380. (Pubitemid 39496831)
28. Stiborová M, Rupertová M. Schmeiser HH and Frei E. (2006). Molecular mechanism of antineoplastic action of an anticancer drug ellipticine. Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub 150: 13-23.
29. Stiborová M, Poljaková J, Rylavá H, Dracínský M, Eckschlager T and Frei E. (2007a). Mammalian peroxidases activate anticancer drug ellipticine to intermediates forming deoxyguanosine adducts in DNA identical to those found in vivo and generated from 12-hydroxyellipticine and 13-hydroxyel-lipticine. Int J Cancer 120: 243-251. (Pubitemid 44956832)
30. Stiborová M, Rupertová M, Aimová D, Rylavá H and Frei E. (2007b). Formation and persistence of DNA adducts of anticancer drug ellipticine in rats. Toxicology 236: 50-60. (Pubitemid 46777068)
31. Stiborová M, Arlt VM, Henderson CJ, Wolf CR, Kotrbová V, Moserová M, Hudecek J, Phillips DH and Frei E. (2008). Role of hepatic cytochromes P450 in bioactivation of the anticancer drug ellipticine: studies with the hepatic NADPH:cytochrome P450 reductase null mouse. Toxicol Appl Pharmacol 226: 318-327. (Pubitemid 351172414)
32. Stiborová M, Rupertová M and Frei E. (2011). Cytochrome P450-and peroxi-dase-mediated oxidation of anticancer alkaloid ellipticine dictates its anti-tumor efciency. Biochim Biophys Acta 1814: 175-185.
33. Sugikawa E, Hosoi T, Yazaki N, Gamanuma N, Nakanishi N and Ohashi M. (1999). Mutant p53 mediated induction of cell cycle arrest and apoptosis at G1 phase by 9-hydroxyellipticine. Anticancer Res 19: 3099-3108. (Pubitemid 30042597)